Technology

Celyad Oncology

$8.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.06 (+0.70%) As of 3:55 PM UTC today

Why Robinhood?

You can buy or sell CYAD and other stocks, options, and ETFs commission-free!

About CYAD

Celyad Oncology SA engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium. The listed name for CYAD is Celyad Oncology SA American Depositary Shares.

CEO
Filippo Joseph Petti
Employees
107
Headquarters
Mont-Saint-Guibert, Walloon Region
Founded
2007
Market Cap
119.58M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
20.43K
High Today
$8.70
Low Today
$8.44
Open Price
$8.70
Volume
15.07K
52 Week High
$13.01
52 Week Low
$4.10

Collections

CYAD News

BenzingaJan 19

Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In

CYAD Earnings

Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 5, Pre-Market

You May Also Like

BBSA
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure